Affinage

Showing FBXW7 — CDC4 is a alias.

FBXW7

F-box/WD repeat-containing protein 7 · UniProt Q969H0

Length
707 aa
Mass
79.7 kDa
Annotated
2026-06-09
100 papers in source corpus 46 papers cited in narrative 46 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FBXW7 is the substrate-recognition subunit of an SCF (SKP1-CUL1-RBX1)-type E3 ubiquitin ligase that uses its WD40 repeat domain to capture phosphorylated degron motifs on diverse regulatory proteins and target them for polyubiquitination and proteasomal degradation, thereby restraining cell proliferation, differentiation, and tissue homeostasis (PMID:11585921, PMID:19679664, PMID:35395208). Its earliest characterized substrates were the Notch1 and Notch4 intracellular domains, which it binds in the nucleus in a phosphorylation-dependent manner to terminate Notch transcriptional output (PMID:11461910, PMID:11425854, PMID:11585921); genetic loss in mouse confirmed Notch4 accumulation as the cause of embryonic vascular remodeling defects (PMID:14672936), and conditional deletions established Notch and N-terminally phosphorylated c-Jun as the critical substrates governing neural, cerebellar, hepatic, and intestinal stem/progenitor cell viability and lineage choice (PMID:20935640, PMID:21123947, PMID:21282377, PMID:21827743). Substrate engagement is governed by prior phosphorylation of a Cdc4 phosphodegron by upstream kinases — GSK3 for KLF2, SOX9, GFI1, Mcl-1, and ERRα; CDK1 for REV-ERBα; CDK5 for NDE1; CK1δ for Brg1/SMARCA4; ATM for p53; and ERK for the Braf ortholog LIN-45 — extending FBXW7 control to angiogenesis, ciliary length, circadian rhythm, chromatin remodeling, DNA-damage responses, and metabolism (PMID:23507969, PMID:27625374, PMID:31289136, PMID:28619760, PMID:35440636, PMID:27238018, PMID:26206584, PMID:30177679, PMID:31940492, PMID:23154983). The nucleoplasmic Fbw7α isoform accounts for essentially all activity toward cyclin E, c-Myc, and SREBP1 (PMID:18559665), and germline missense variants clustering at the WD40 substrate-binding surface impair cyclin E turnover and cause a neurodevelopmental disorder (PMID:35395208). FBXW7 abundance is itself tightly controlled: the deubiquitinase USP9X stabilizes FBXW7 while USP28 removes ubiquitin from FBXW7 substrates (PMID:29346117, PMID:25716680, PMID:25437563), and FBXW7 is destabilized by ERK- and DYRK2-mediated phosphorylation, by LSD1 acting as a dimerization-blocking pseudosubstrate that triggers self-ubiquitylation, and by FBXO45-MYCBP2 and TRIP12-mediated branched K11 ubiquitylation (PMID:25753158, PMID:36934104, PMID:31152129, PMID:31285543, PMID:33824312). Through this substrate network and layered regulation FBXW7 functions as a broadly acting tumor suppressor whose inactivation promotes oncoprotein accumulation, metastasis, and therapy resistance (PMID:27625374, PMID:25555218, PMID:32371478).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2001 High

    Established FBXW7 (SEL-10) as a nuclear ubiquitin ligase component that recognizes the active, phosphorylated intracellular domains of Notch receptors, answering how Notch signaling is terminated.

    Evidence Co-IP, in vitro/in vivo ubiquitination, dominant-negative F-box deletion, and reporter assays for Notch1 and Notch4 ICDs in mammalian cells

    PMID:11425854 PMID:11461910 PMID:11585921

    Open questions at the time
    • Did not resolve which kinase phosphorylates the Notch degron
    • SCF complex assembly not biochemically reconstituted at this stage
  2. 2002 Medium

    Extended substrate scope to presenilin 1 and APP metabolism, linking FBXW7 to amyloid processing.

    Evidence Co-IP and ubiquitination assays with PS1/APP co-transfection in HEK293 cells

    PMID:12354302

    Open questions at the time
    • Single study without independent replication
    • No degron mapping on PS1
    • Physiological relevance to amyloid biology not tested in vivo
  3. 2003 High

    Demonstrated in vivo physiological necessity of FBXW7, showing that embryonic vascular remodeling depends on substrate-specific degradation of Notch4.

    Evidence Fbxw7-null mouse knockout with substrate immunoblotting and explant culture

    PMID:14672936

    Open questions at the time
    • Embryonic lethality precluded analysis of later tissues
    • Substrate selectivity (Notch4 over Notch1-3/cyclin E) mechanism unexplained
  4. 2007 Medium

    Revealed counter-regulation by deubiquitinases and viral antagonism, showing FBXW7 activity is dynamically opposed at the substrate level.

    Evidence Co-IP and substrate stability assays for USP28-Fbw7α with UV; competition binding for KSHV LANA

    PMID:17873522 PMID:17909182

    Open questions at the time
    • Isoform-specific USP28 interaction not structurally defined
    • LANA studies limited to single lab in infected cells
  5. 2008 High

    Defined the three FBXW7 isoforms and established the nucleoplasmic Fbw7α as the dominant active species toward cyclin E, c-Myc, and SREBP1, explaining where ligase activity resides.

    Evidence AAV-mediated isoform-specific gene targeting in human cells with substrate turnover and cell-cycle synchronization

    PMID:18559665

    Open questions at the time
    • Functions of β and γ isoforms left undefined
    • Cell-cycle modulation of cyclin E sensitivity mechanistically incomplete
  6. 2009 High

    Showed oncoproteins can inhibit the catalytic core of the SCF(Fbw7) complex directly, a regulatory mode distinct from substrate competition.

    Evidence In vitro reconstituted ubiquitin ligase assay with purified Roc1/Rbx1-CUL1 plus in vivo substrate stability with adenovirus E1A

    PMID:19679664

    Open questions at the time
    • Whether endogenous cellular factors use the same inhibition mode unknown
  7. 2011 High

    Conditional tissue knockouts identified c-Jun, Notch, and DEK as the physiologically relevant substrates governing neural, cerebellar, hepatic, and intestinal stem/progenitor cell fate and tumorigenesis.

    Evidence Tissue-specific Cre knockouts with genetic epistasis (c-Jun deletion, junAA knock-in, RBP-J deletion, Apc-Min compound) and substrate immunoblotting

    PMID:20935640 PMID:21123947 PMID:21282377 PMID:21827743

    Open questions at the time
    • Relative contribution of each substrate varies by tissue and is not fully partitioned
    • DEK degron not mapped
  8. 2012 High

    Defined the Cdc4 phosphodegron logic in vivo, showing ERK-driven phosphorylation creates the degron that recruits the ligase to Braf/LIN-45 in a feedback loop.

    Evidence C. elegans genetics with CPD mutagenesis and sel-10/mpk-1 epistasis

    PMID:23154983

    Open questions at the time
    • Direct mammalian BRAF degradation by FBXW7 not tested here
  9. 2016 High

    Generalized the kinase-primed degron paradigm across substrates and physiological axes, with distinct upstream kinases dictating recognition of KLF2, SOX9, REV-ERBα, NDE1, and others.

    Evidence Degron/phosphodegron mutagenesis, ubiquitination assays, kinase assays (GSK3, CDK1, CDK5, CK1δ) with functional readouts in angiogenesis, circadian, ciliary, and metastasis models

    PMID:23507969 PMID:26206584 PMID:27238018 PMID:27625374 PMID:30177679

    Open questions at the time
    • Structural basis for differential degron affinity across substrates incomplete
    • Crosstalk between competing substrates not quantified
  10. 2017 High

    Provided structural/biochemical detail of multisite phosphodegron recognition, showing Pin1-catalyzed proline isomerization tunes c-Jun affinity for the WD40 domain.

    Evidence NMR spectroscopy and fluorescence binding with phosphorylation mapping and Pin1 interaction studies

    PMID:29225075

    Open questions at the time
    • Whether isomerase tuning applies to other FBXW7 substrates not tested
  11. 2018 High

    Mapped the layered control of FBXW7's own stability, identifying USP9X as a stabilizing deubiquitinase, USP28 as a dual antagonist, and LSD1 as a dimerization-blocking pseudosubstrate driving self-degradation.

    Evidence Proteomics, Co-IP, conditional Usp9x/Usp28 knockouts with c-Myc epistasis, dimerization assays, catalytic mutants, and proteasome/lysosome inhibitors

    PMID:25437563 PMID:25716680 PMID:29346117 PMID:31152129

    Open questions at the time
    • Quantitative balance between stabilizing and destabilizing inputs in normal cells unresolved
  12. 2020 High

    Identified destabilizing post-translational and E3-ligase inputs (ERK-T205, FBXO45-MYCBP2, TRIP12 branched K11 ubiquitylation) and broadened substrate scope to p53, TPP1, EZH2, and immune/metabolic regulators.

    Evidence Kinase assays, domain mapping, ubiquitin-linkage-specific analysis, shRNA screen, conditional knockouts, and functional models of mitotic slippage, senescence, fibrosis, and immunotherapy response

    PMID:25753158 PMID:31246581 PMID:31285543 PMID:31940492 PMID:32371478 PMID:33086033 PMID:33824312

    Open questions at the time
    • Some substrate claims (e.g., dsRNA sensors) remain correlative
    • Hierarchy of the multiple FBXW7-destabilizing E3 ligases unclear
  13. 2022 High

    Established a causative Mendelian link, showing germline WD40 substrate-surface missense variants impair cyclin E turnover and cause a neurodevelopmental disorder.

    Evidence Structural modeling, recombinant variant cyclin E turnover assays, Drosophila pan-neuronal RNAi, and a clinical genetic cohort

    PMID:35395208

    Open questions at the time
    • Which substrate(s) beyond cyclin E drive the neurodevelopmental phenotype not fully defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the dozens of competing phosphodegron substrates are prioritized within a single cell, and how the multiple destabilizing kinases and E3 ligases are integrated to set net FBXW7 activity in a given tissue, remains unresolved.
  • No quantitative model of substrate competition
  • Tissue-specific regulatory hierarchy of FBXW7 stability inputs undefined
  • Structural basis of branched-ubiquitin recognition by the proteasome not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016874 ligase activity 5 GO:0140096 catalytic activity, acting on a protein 5 GO:0098772 molecular function regulator activity 3 GO:0060089 molecular transducer activity 2
Localization
GO:0005634 nucleus 3 GO:0005654 nucleoplasm 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1640170 Cell Cycle 4 R-HSA-1643685 Disease 4 R-HSA-392499 Metabolism of proteins 4 R-HSA-1266738 Developmental Biology 3 R-HSA-1430728 Metabolism 3 R-HSA-168256 Immune System 3 R-HSA-9909396 Circadian clock 1
Partners
CUL1DYRK2FBXO45LSD1RBX1TRIP12USP28USP9X
Complex memberships
SCF(FBXW7) (SKP1-CUL1-RBX1-FBXW7) E3 ubiquitin ligase

Evidence

Reading pass · 46 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 Mammalian SEL-10/mSel-10 (FBXW7) physically interacts with the Notch1 intracellular domain (IC) in the cell nucleus, ubiquitinates Notch1 IC in a manner requiring the PEST domain at the C-terminal region, and reduces Notch1 IC-mediated activation of the HES1 promoter. Ubiquitinated Notch1 IC accumulates in the presence of proteasome inhibitor MG132 but is a less potent transactivator, indicating that ubiquitination itself reduces Notch activity independent of degradation. Co-immunoprecipitation, in vivo ubiquitination assay, reporter gene assay (HES1 promoter), proteasome inhibitor treatment, nuclear localization by subcellular fractionation The Journal of biological chemistry High 11461910
2001 Human SEL-10 specifically interacts with nuclear (active transcriptional factor) forms of Notch1, not with inactive membrane-anchored forms, and this interaction requires a phosphorylation event. A dominant-negative SEL-10 (F-box deleted) stabilizes intracellular Notch1 and enhances its transcriptional activity. Notch1 IC undergoes polyubiquitination in vitro and is stabilized by proteasome inhibitors in vivo. Dominant-negative expression, co-immunoprecipitation, in vitro ubiquitination assay, proteasome inhibitor treatment The Journal of biological chemistry High 11425854
2001 SEL-10 negatively regulates Notch1 and Notch4 receptor activity by targeting their intracellular domains for ubiquitin-mediated proteasomal degradation via its WD40 repeats. SEL-10 binds preferentially to a phosphorylated form of Notch4 IC; binding requires the C-terminal region of Notch4 downstream of the ankyrin repeats. In vitro ubiquitination of Notch1 and Notch4 IC is dependent on SEL-10. Dominant-negative expression, co-immunoprecipitation, in vitro ubiquitination assay, Notch signaling reporter assay Molecular and cellular biology High 11585921
2003 Mouse Fbxw7 is required for vascular development; Fbxw7-null embryos die at E10.5-11.5 with impaired vascular remodeling. In Fbxw7-/- embryos, Notch4 (but not Notch1, -2, or -3 or cyclin E) specifically accumulates, resulting in increased expression of Hey1, a downstream Notch transcriptional repressor implicated in vascular development. Genetic knockout (Fbxw7-/- mice), immunoblotting for substrates, in vitro para-aortic explant culture, gene expression analysis The Journal of biological chemistry High 14672936
2002 Human SEL-10 (FBXW7) interacts with presenilin 1 (PS1) and enhances PS1 ubiquitination, altering cellular levels of unprocessed PS1 and its N- and C-terminal fragments. Co-transfection of sel-10 and APP in HEK293 cells alters APP metabolism and increases amyloid beta-peptide production. Co-immunoprecipitation, ubiquitination assay, co-transfection in HEK293 cells, western blot Journal of neurochemistry Medium 12354302
2007 Fbw7 mediates proteasomal degradation of the Myc oncoprotein in response to DNA damage (UV irradiation). The ubiquitin-specific protease Usp28 binds to the nucleoplasmic isoform Fbw7alpha and counteracts Fbw7-mediated Myc degradation; UV irradiation causes Usp28 to dissociate from Fbw7alpha, thereby enhancing Fbw7-mediated Myc degradation. Proteasome inhibitor assays, co-immunoprecipitation, western blot following UV irradiation, overexpression/knockdown Cell cycle Medium 17873522
2008 The Fbxw7 locus encodes three isoforms (alpha, beta, gamma) with distinct subcellular localizations. The nucleoplasmic Fbw7alpha isoform accounts for almost all Fbw7 activity toward cyclin E, c-Myc, and SREBP1. Cyclin E sensitivity to Fbw7 varies during the cell cycle, correlating with changes in cyclin E-CDK2-specific activity, cyclin E autophosphorylation, and CDK2 inhibitory phosphorylation. Isoform-specific gene targeting (AAV-mediated) in human cells, substrate turnover assays, cell-cycle synchronization The Journal of cell biology High 18559665
2009 Adenovirus E1A oncoprotein inhibits SCF(Fbw7) ubiquitin ligase activity by directly binding to Roc1/Rbx1 and CUL1 subunits of the SCF complex. E1A inhibits the ubiquitin ligase activity of the Roc1/Rbx1-CUL1 complex in vitro (but not that of Mdm2), and decelerates degradation of SCF(Fbw7) substrates in vivo. In vitro ubiquitin ligase assay with purified SCF components, co-immunoprecipitation, in vivo substrate stability assay, viral infection The Journal of biological chemistry High 19679664
2010 Fbxw7 controls neural stem and progenitor cell (NSC/NPC) viability and differentiation in the mouse brain. Fbxw7 deficiency causes accumulation of active Notch1 and N-terminally phosphorylated c-Jun. Genetic and pharmacological rescue experiments established that c-Jun is the key Fbxw7 substrate controlling progenitor cell viability, while Notch signaling inhibition alleviates the block in stem cell differentiation. Conditional neural-specific Fbxw7 knockout mice, genetic epistasis (Notch inhibitor, c-Jun deletion), substrate immunoblotting Nature neuroscience High 20935640
2010 Hepatic ablation of Fbxw7 results in hepatomegaly and steatohepatitis with massive triglyceride deposition, and skews liver stem cell differentiation toward the cholangiocyte lineage rather than hepatocyte lineage. Additional loss of Notch cofactor RBP-J corrects the biliary proliferation bias, establishing Notch accumulation as the causal mechanism. Liver-specific conditional knockout (Mx1-Cre and Alb-Cre), substrate immunoblotting, differentiation assays in vitro, genetic epistasis with RBP-J The Journal of clinical investigation High 21123947
2011 Intestine-specific deletion of Fbxw7 in mice elevates Notch, c-Jun, and DEK protooncogene expression. DEK accumulation promotes cell division and alters splicing of tropomyosin (TPM) RNA. In the context of APC deficiency, Fbxw7 loss accelerates tumorigenesis and promotes β-catenin accumulation at late time points. Conditional gut-specific knockout (Villin-Cre), compound genetic models (Apc-Min/+), immunoblotting, RNA splicing analysis, genetic epistasis The Journal of experimental medicine High 21282377
2011 Fbxw7 is required for cerebellar development; conditional deletion in the cerebellar anlage reduces Purkinje cell number and causes axonal arborization defects. Protein levels of Notch1 and N-terminally phosphorylated c-Jun are elevated. Concomitant deletion of c-Jun (or junAA knock-in abrogating c-Jun N-terminal phosphorylation) rescues Purkinje cell numbers and arborization, identifying N-terminally phosphorylated c-Jun as an important Fbxw7 substrate during neurogenesis. Conditional cerebellar Fbxw7 knockout, genetic rescue (c-Jun deletion, junAA knock-in), substrate immunoblotting Developmental biology High 21827743
2012 In C. elegans, SEL-10 (Fbxw7 ortholog) regulates degradation of LIN-45/Braf through a Cdc4 phosphodegron (CPD). MPK-1/ERK activity is required for LIN-45 protein degradation in a negative feedback loop: where ERK is highly active, LIN-45 is degraded by SEL-10. Mutation of the CPD in LIN-45 or loss of sel-10 results in increased LIN-45 activity and protein stability in vivo. C. elegans genetics, CPD mutant analysis, epistasis with sel-10 and mpk-1, in vivo protein stability assay Genes & development High 23154983
2013 FBW7 targets KLF2 for ubiquitination and proteasomal degradation in endothelial cells. GSK3-mediated phosphorylation of KLF2 at two conserved phosphodegron motifs is required for FBW7 binding; mutation of these phosphodegrons abolishes FBW7-mediated KLF2 ubiquitination and degradation. FBW7-mediated KLF2 degradation regulates angiogenesis, leukocyte adhesion, and endothelial barrier integrity in vitro and in vivo (zebrafish). Co-immunoprecipitation, in vivo ubiquitination assay, phosphodegron mutagenesis, siRNA knockdown, angiogenesis assays in vitro and in zebrafish Cell research High 23507969
2015 ERK directly interacts with FBW7 and phosphorylates FBW7 at Thr205, which promotes FBW7 ubiquitination and proteasomal degradation. A phospho-deficient T205A FBW7 mutant is resistant to ERK-mediated degradation. This mechanism explains how oncogenic KRAS mutations impair FBW7 tumor suppressor function in pancreatic cancer. Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (T205A), proteasome inhibitor assays, xenograft tumor models Cell research High 25753158
2015 FBW7 mediates cell cycle-dependent ubiquitylation and degradation of NDE1, a negative regulator of ciliary length. CDK5, active in G1/G0, primes NDE1 for FBW7-mediated recognition. Cells depleted of FBW7 or CDK5 show elevated NDE1 levels and reduced ciliary length; this phenotype is corrected by co-depletion of NDE1, placing NDE1 downstream of CDK5-FBW7 in the ciliary length regulatory pathway. Co-immunoprecipitation, ubiquitination assay, genetic epistasis (FBW7/CDK5/NDE1 siRNA co-depletion), ciliary length measurement, cell cycle synchronization The EMBO journal High 26206584
2015 FBW7 targets ENO1 for ubiquitin-mediated degradation. FBXW7 physically binds ENO1 and its depletion increases ENO1 protein levels; overexpression of FBXW7 suppresses ENO1-induced lactate production, cell proliferation, and migration. 2D gel/mass spectrometry to identify substrate, co-immunoprecipitation, in vivo ubiquitination assay, functional proliferation and migration assays Laboratory investigation Medium 26097998
2015 Usp28 deubiquitinates Fbw7 substrates (NICD1, c-Jun, c-Myc) independently of Fbw7, recognizing their unphosphorylated phosphodegron motif (while Fbw7 binds the phosphorylated form). Genetic deletion of Usp28 rescues lethality of Fbw7-deficient fibroblasts and corrects substrate accumulation in intestinal cells, indicating direct antagonism between Fbw7 and Usp28 on the same substrates. Genetic deletion of Usp28 in Fbw7-deficient backgrounds, conditional intestine-specific knockouts, substrate immunoblotting, compound mutant mice Cancer research High 25716680
2014 Usp28 preferentially antagonizes autocatalytic (self-)ubiquitination of Fbw7, thereby stabilizing Fbw7 protein. Monoallelic Usp28 deletion maintains stable Fbw7 and drives substrate degradation; complete Usp28 knockout triggers Fbw7 degradation and substrate accumulation. Overexpression of Usp28 stabilizes both Fbw7 and its substrates. Both loss and overexpression of Usp28 promote Ras-driven oncogenic transformation. Usp28 conditional and complete knockout mice, substrate immunoblotting, oncogenic transformation assays, MEF studies Cell reports High 25437563
2016 SOX9 is a direct substrate of FBW7. FBW7 recognizes a conserved degron surrounding Thr236 in SOX9 phosphorylated by GSK3 kinase; SCFFBW7alpha mediates subsequent SOX9 proteasomal degradation. Failure to degrade SOX9 promotes migration, metastasis, and treatment resistance in medulloblastoma. Pharmacological PI3K/AKT/mTOR inhibition destabilizes SOX9 in a GSK3/FBW7-dependent manner. Co-immunoprecipitation, in vivo ubiquitination assay, degron mutagenesis, conditional knockout, xenograft/migration/metastasis assays, pharmacological rescue The EMBO journal High 27625374
2016 CDK1-mediated phosphorylation of REV-ERBα is required for FBXW7 recognition. FBXW7 ubiquitinates REV-ERBα and targets it for degradation, relieving REV-ERBα-dependent repression and enhancing circadian clock gene transcription amplitude. Hepatic disruption of FBXW7 alters circadian expression of core clock genes and perturbs whole-body lipid and glucose levels. Co-immunoprecipitation, in vivo ubiquitination assay, kinase assay, liver-specific FBXW7 knockout, circadian gene expression profiling, metabolic phenotyping Cell High 27238018
2017 Multisite phosphorylation of c-Jun is required for high-affinity interaction with the WD40 domain of Fbw7. Pin1 (prolyl isomerase) interacts with the multiply phosphorylated disordered region of c-Jun and isomerizes a pSer-Pro peptide bond at the c-Jun N-terminus, which modulates c-Jun binding to Fbw7 and thereby regulates ubiquitin-mediated c-Jun degradation. NMR spectroscopy, fluorescence binding assays, c-Jun phosphorylation mapping, Pin1 domain interaction studies Structure High 29225075
2018 SCFFBW7 targets Brg1/SMARCA4 (ATPase subunit of SWI/SNF) for ubiquitination and proteasomal degradation. CK1δ phosphorylates Brg1 at Ser31/Ser35 to facilitate FBW7 binding; phospho-deficient mutations abolish FBW7-mediated Brg1 degradation. Brg1 stabilization in gastric cancer cells suppresses E-cadherin expression, promoting metastasis. Co-immunoprecipitation, in vivo ubiquitination assay, CK1δ kinase assay, phosphodegron mutagenesis, E-cadherin expression analysis, clinical sample correlation Nature communications High 30177679
2018 The deubiquitinase USP9X interacts with FBW7, antagonizes FBW7 ubiquitylation, and stabilizes FBW7 protein. Deletion of Usp9x causes Fbw7 destabilization, increased c-Myc levels, reduced secretory cell differentiation, and increased intestinal tumor burden. c-Myc heterozygosity abrogates the increased proliferation and tumor burden in Usp9x-deficient mice, placing USP9X upstream of FBW7 and c-Myc. Proteomics/MS to identify USP9X, co-immunoprecipitation, conditional gut-specific Usp9x knockout, genetic epistasis with c-Myc heterozygosity, tumor burden analysis The Journal of clinical investigation High 29346117
2019 FBXW7 degrades EZH2 in macrophages, suppressing H3K27me3 modification and thereby promoting Ccl2 and Ccl7 expression. In CX3CR1hi resident macrophages, FBXW7 deficiency results in decreased CCL2/CCL7 production and reduced accumulation of pro-inflammatory macrophages in colitis. Co-immunoprecipitation, ubiquitination assay, myeloid-specific conditional knockout, colitis models (DSS and TNBS), AAV-shFbxw7 in vivo, chromatin analysis The Journal of clinical investigation High 31246581
2019 FBXO45-MYCBP2 E3 ubiquitin ligase targets FBXW7 for ubiquitylation and proteasomal degradation during prolonged mitotic arrest. FBXO45 binds a conserved acidic N-terminal motif of FBXW7 specifically under conditions of extended mitotic delay, reducing FBXW7 levels and thereby promoting mitotic slippage over cell death. Co-immunoprecipitation, ubiquitination assay, FBXW7 domain mapping, overexpression/knockdown, mitotic slippage assay Cell death and differentiation High 31285543
2019 SCFFBXW7/GSK3β targets GFI1 transcription factor for degradation. GSK3β-mediated GFI1 phosphorylation at S94/S98 triggers interaction with FBXW7 and subsequent SCFFBW7-mediated ubiquitination and degradation. A non-degradable GFI1 S94A/S98A mutant more potently drives gastric cancer cell proliferation than wild-type GFI1. Co-immunoprecipitation, in vivo ubiquitination assay, phosphodegron mutagenesis (S94A/S98A), kinase assay, proliferation/tumorigenesis assays Cancer research High 31289136
2019 LSD1 (KDM1A) directly binds FBXW7 and acts as a pseudosubstrate, promoting FBXW7 self-ubiquitylation by preventing FBXW7 dimerization. LSD1-FBXW7 binding does not trigger LSD1 ubiquitylation but destabilizes FBXW7 in a manner independent of LSD1 demethylase activity. Self-ubiquitylated FBXW7 is degraded by both proteasome and lysosome/autophagy (p62/SQSTM1-dependent). Co-immunoprecipitation, ubiquitination assay, dimerization assays, LSD1 catalytic mutant, proteasome and lysosome inhibitors, autophagy pathway analysis Proceedings of the National Academy of Sciences of the United States of America High 31152129
2020 FBXW7 binds to telomere protection protein 1 (TPP1) and facilitates TPP1 multisite polyubiquitination and degradation, triggering telomere uncapping and DNA damage response. This mechanism underlies stress-induced cell senescence and pulmonary fibrosis. Overexpressing TPP1 or inhibiting FBW7 reduces telomere uncapping and shortening. Co-immunoprecipitation, ubiquitination assay, FBW7 genetic ablation, telomere dysfunction assays, mouse pulmonary fibrosis models Cell metabolism High 33086033
2020 FBXW7 inactivation leads to decreased tumor-intrinsic expression of the dsRNA sensors MDA5 and RIG-1 and diminished induction of type I IFN and MHC-I expression, causing resistance to anti-PD-1 immunotherapy. Restoration of dsRNA sensing in Fbxw7-deficient cells sensitizes them to anti-PD-1. Comparative tumor sequencing, Fbxw7 knockout in murine tumor lines, anti-PD-1 treatment in immunocompetent animals, gene expression analysis, dsRNA sensing pathway reconstitution Cancer discovery Medium 32371478
2020 FBXW7 inhibits expression of stearoyl-CoA desaturase (SCD1) via inhibiting nuclear receptor NR4A1 (NRA41), which suppresses lipid peroxidation and promotes ferroptosis as well as apoptosis in pancreatic cancer cells. Gene expression profiling, targeted metabolite analysis, co-expression studies, in vitro ferroptosis and apoptosis assays, xenograft models Redox biology Medium 33271455
2020 FBXW7 interacts with and targets p53 for polyubiquitination and proteasomal degradation following ionizing radiation or etoposide. ATM phosphorylates p53 on Ser33 and Ser37 after DNA damage, facilitating FBXW7 binding and subsequent p53 degradation. Inactivation of ATM or SCFFBXW7 extends p53 half-life in an MDM2-independent manner. Co-immunoprecipitation, in vivo ubiquitination assay, ATM inhibitor, kinase assay, half-life measurements, FBXW7 genetic knockout Cell reports High 31940492
2021 FBW7 is identified as a novel E3 ubiquitin ligase for IκBα; FBW7 upregulation promotes IκBα ubiquitin-dependent degradation and NF-κB activation in intestinal epithelial cells, thereby promoting intestinal inflammation. Co-immunoprecipitation, ubiquitination assay, FBW7 overexpression/knockdown, NF-κB reporter assay, in vivo colitis model Molecular therapy. Nucleic acids Medium 31945730
2021 FBW7 suppresses ovarian cancer by targeting the m6A reader YTHDF2 for proteasomal degradation. FBW7 interacts with YTHDF2 and induces its ubiquitination; FBW7 loss stabilizes YTHDF2, which promotes decay of the pro-apoptotic gene BMF mRNA. IP-MS, co-immunoprecipitation, ubiquitination assay, in vitro and in vivo tumor models, MeRIP-Seq/RNA-Seq Molecular cancer High 33658012
2021 Proteasomal degradation of FBW7 requires branched ubiquitylation: SCFFBW7-mediated ubiquitylation of FBW7 on K404 and K412 is necessary but not sufficient for proteasomal degradation. TRIP12 (HECT-domain E3 ligase) additionally mediates branched K11-linked ubiquitylation of FBW7, which is required for its degradation. TRIP12 inactivation causes FBW7 accumulation and increased MCL1 degradation. shRNA library screen, co-immunoprecipitation, ubiquitin linkage-specific analysis, TRIP12 inactivation, substrate (MCL1) turnover assay Nature communications High 33824312
2022 Germline monoallelic FBXW7 missense variants cluster at the substrate-binding surface of the WD40 domain and cause impaired CYCLIN E1 and CYCLIN E2 turnover, as shown by expression of recombinant FBXW7 missense variants in cultured cells. Pan-neuronal knockdown of the Drosophila ortholog archipelago impairs learning and neuronal function, establishing that FBXW7's ubiquitin ligase activity toward cyclin E substrates is essential for normal neurodevelopment. Structural modeling of WD40 domain, recombinant variant expression with cyclin E turnover assay, Drosophila pan-neuronal RNAi, clinical genetic cohort American journal of human genetics High 35395208
2022 Insulin enhances ERRα activity via a GSK3β/FBXW7 signaling axis: GSK3β phosphorylates ERRα at multiple sites enabling FBXW7-mediated degradation. Liver-specific deletion of GSK3β or FBXW7, or expression of non-degradable ERRα3SA phosphosite mutants, results in accumulated ERRα that no longer responds to fluctuating insulin levels, causing compromised energy homeostasis and reduced insulin sensitivity. Conditional liver-specific knockouts (GSK3β, FBXW7), phosphosite knock-in mutant mice (ERRα3SA), ubiquitination assay, transcriptome analysis, metabolic phenotyping Nature communications High 35440636
2022 Mechanical overloading decreases FBXW7-mediated MKK7 degradation, leading to enhanced JNK signaling and chondrocyte senescence. Intra-articular injection of adenovirus expressing Fbxw7 alleviates osteoarthritis in mice by restoring MKK7 degradation. Chondrocyte-specific Fbxw7 knockout, intra-articular AAV delivery, substrate (MKK7) analysis, JNK signaling assay, in vitro mechanical stress model, OA scoring Annals of the rheumatic diseases Medium 35058228
2022 FBW7 together with GSK3β recognizes and degrades IGF2BP2 (m6A reader). GSK3β-mediated phosphorylation facilitates FBXW7-dependent ubiquitination of IGF2BP2, which inhibits the IGF2BP2-SLC7A5 positive feedback loop and reduces lung cancer radioresistance. Co-immunoprecipitation, ubiquitination assay, ChIP-qPCR, RIP/MeRIP-qPCR, RNA pulldown, clonogenic survival assay, xenograft models Journal of experimental & clinical cancer research Medium 38281999
2022 FBXW7-mediated ERK3 ubiquitination and proteasomal degradation requires binding between ERK3's C34D region (specifically Thr417 and Thr421) and the WD40 domain of FBXW7. Double mutation of ERK3 Thr417/Thr421 to alanine abolishes FBXW7-mediated ubiquitination. Mammalian two-hybrid assay, co-immunoprecipitation, ubiquitination assay, domain mutagenesis, ERK3 knockdown/proliferation assays Experimental & molecular medicine Medium 35022544
2007 Kaposi's sarcoma-associated herpesvirus (KSHV) LANA directly interacts with Sel10/FBXW7 via LANA's C-terminus with the F-box and WD40 domains of Sel10. LANA-Sel10 complex formation suppresses ICN (intracellular Notch) ubiquitination and degradation by competing with ICN for Sel10 binding, resulting in elevated ICN levels in KSHV-infected cells. Co-immunoprecipitation, in vivo ubiquitination assay, competition binding assay, KSHV-infected cell analysis Proceedings of the National Academy of Sciences of the United States of America Medium 17909182
2015 FBXW7 regulates CCDC6 turnover in a cell-cycle-dependent manner. Mitotic kinases and degron motifs in CCDC6 direct CCDC6 recruitment to FBXW7 E3 ligase; CCDC6 undergoes cyclic phosphorylation and protein level changes peaking at G2 and decreasing in mitosis. The deubiquitinase USP7 fine-tunes CCDC6 stability. Co-immunoprecipitation, cell cycle synchronization, ubiquitination assay, CCDC6 protein stability analysis, USP7 interaction studies Oncotarget Medium 25885523
2023 DYRK2 serine/threonine kinase directly interacts with and phosphorylates FBXW7, causing its proteasome-mediated degradation independent of FBXW7's own ubiquitin ligase activity. DYRK2-dependent FBXW7 destabilization alters levels of key FBXW7 substrates and affects cellular responses to chemotherapy agents (doxorubicin, paclitaxel) and BET inhibitors. Co-immunoprecipitation, kinase assay, proteasome inhibitor assay, substrate readout, functional drug response assays Cell death & disease Medium 36934104
2015 PKM2 (pyruvate kinase M2) is a bona fide ubiquitin substrate of SCFFBW7 in macrophages. FBW7-deficient macrophages show increased PKM2 levels with decreased pentose phosphate pathway flux (reduced NADPH/GSH), enhanced ROS production, and exacerbated proinflammatory responses and insulin resistance. Co-immunoprecipitation, ubiquitination assay, myeloid-specific FBW7 knockout, metabolic flux analysis, PKM2 inhibitor, redox measurements Redox biology Medium 32853822
2017 FBW7-dependent Mcl-1 degradation is the primary mechanism by which Hsp90 inhibitors kill colorectal cancer cells. Hsp90 inhibition promotes GSK3β-dependent phosphorylation of Mcl-1, which then binds FBW7 and undergoes ubiquitination and proteasomal degradation. Blocking Mcl-1 phosphorylation by genetic knock-in abrogates its degradation and confers resistance to Hsp90 inhibitors. Co-immunoprecipitation, ubiquitination assay, Mcl-1 phospho knock-in, GSK3β inhibition, in vitro and in vivo Hsp90 inhibitor sensitivity assays Molecular cancer therapeutics High 28619760
2015 Fbxw7 deletion in murine bone marrow-derived stromal cells induces accumulation of NOTCH and transcriptional activation of Ccl2, leading to increased serum CCL2. Elevated CCL2 recruits monocytic myeloid-derived suppressor cells and macrophages to promote metastatic tumor growth in a non-cell-autonomous manner. Conditional Fbxw7 knockout in stromal/BM cells, NOTCH substrate immunoblotting, CCL2 serum measurement, pharmacological CCL2 receptor antagonism, tumor metastasis models The Journal of clinical investigation High 25555218

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature reviews. Cancer 931 18094723
2018 Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. Journal of the National Cancer Institute 901 28903484
2018 FBXW7: a critical tumor suppressor of human cancers. Molecular cancer 422 30086763
2001 The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. The Journal of biological chemistry 340 11461910
2001 Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. The Journal of biological chemistry 317 11425854
2014 Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer cell 305 25314076
2001 SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Molecular and cellular biology 290 11585921
2003 Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. The Journal of biological chemistry 219 14672936
2020 FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Redox biology 218 33271455
2003 BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. The American journal of pathology 186 14507635
2011 FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. The Journal of experimental medicine 157 21282377
2022 Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7. Annals of the rheumatic diseases 148 35058228
2010 Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nature neuroscience 148 20935640
2010 Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. International journal of cancer 137 19739118
2012 Tumor suppressor functions of FBW7 in cancer development and progression. FEBS letters 136 22673505
2019 FBXW7 in Cancer: What Has Been Unraveled Thus Far? Cancers 131 30791487
2016 Circadian Amplitude Regulation via FBXW7-Targeted REV-ERBα Degradation. Cell 130 27238018
2015 ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell research 127 25753158
2019 Fbxw7 increases CCL2/7 in CX3CR1hi macrophages to promote intestinal inflammation. The Journal of clinical investigation 120 31246581
2022 Clinical significance of FBXW7 loss of function in human cancers. Molecular cancer 117 35346215
2021 FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. Molecular cancer 108 33658012
2010 Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. The Journal of clinical investigation 108 21123947
2017 Biogenesis and Function of Ago-Associated RNAs. Trends in genetics : TIG 106 28174021
2015 F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. The Journal of clinical investigation 105 25555218
2008 Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. The Journal of cell biology 104 18559665
2007 Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell cycle (Georgetown, Tex.) 104 17873522
2012 The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Frontiers in bioscience (Landmark edition) 100 22652772
2018 The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer. The Journal of clinical investigation 98 29346117
2012 Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer metastasis reviews 98 22124735
2020 Recent insight into the role of FBXW7 as a tumor suppressor. Seminars in cancer biology 93 32113998
2020 FBW7 Mediates Senescence and Pulmonary Fibrosis through Telomere Uncapping. Cell metabolism 91 33086033
2014 FBXW7 mutations in melanoma and a new therapeutic paradigm. Journal of the National Cancer Institute 79 24838835
2013 MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC gastroenterology 79 24053468
2014 Dual regulation of Fbw7 function and oncogenic transformation by Usp28. Cell reports 78 25437563
2020 Circular RNA circFBXW4 suppresses hepatic fibrosis via targeting the miR-18b-3p/FBXW7 axis. Theranostics 73 32308754
2012 Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Molecular and cellular biology 73 22473991
2023 Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. Molecular cancer 71 37393311
2016 FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. The EMBO journal 71 27625374
2015 Cell cycle-dependent ubiquitylation and destruction of NDE1 by CDK5-FBW7 regulates ciliary length. The EMBO journal 71 26206584
2020 FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. Cell reports 70 31940492
2011 Ancestral roles of small RNAs: an Ago-centric perspective. Cold Spring Harbor perspectives in biology 70 20810548
2013 FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. Oncotarget 68 24344117
2019 LSD1 destabilizes FBXW7 and abrogates FBXW7 functions independent of its demethylase activity. Proceedings of the National Academy of Sciences of the United States of America 66 31152129
2018 SCFFBW7-mediated degradation of Brg1 suppresses gastric cancer metastasis. Nature communications 66 30177679
2016 Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis. Medicine 66 26886596
2022 FBXW7 alleviates hyperglycemia-induced endothelial oxidative stress injury via ROS and PARP inhibition. Redox biology 65 36427396
2015 FBXW7 negatively regulates ENO1 expression and function in colorectal cancer. Laboratory investigation; a journal of technical methods and pathology 64 26097998
2020 Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer discovery 62 32371478
2002 SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-beta peptide production. Journal of neurochemistry 60 12354302
2017 FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors. Molecular cancer therapeutics 58 28619760
2015 Usp28 counteracts Fbw7 in intestinal homeostasis and cancer. Cancer research 58 25716680
2013 FBW7 regulates endothelial functions by targeting KLF2 for ubiquitination and degradation. Cell research 58 23507969
2011 Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO reports 57 22157894
2007 Kaposi's sarcoma herpesvirus-encoded latency-associated nuclear antigen stabilizes intracellular activated Notch by targeting the Sel10 protein. Proceedings of the National Academy of Sciences of the United States of America 53 17909182
2015 FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. Oncotarget 47 25885523
2018 Physiological functions of FBW7 in cancer and metabolism. Cellular signalling 45 29474981
2014 NF-κB1 inhibits c-Myc protein degradation through suppression of FBW7 expression. Oncotarget 45 24457827
2015 MYC is a critical target of FBXW7. Oncotarget 43 25669969
2019 Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells. JCI insight 42 30830867
2019 FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation. Cell death and differentiation 42 31285543
2019 A novel transthyretin/STAT4/miR-223-3p/FBXW7 signaling pathway affects neovascularization in diabetic retinopathy. Molecular and cellular endocrinology 42 31415795
2020 Astragalus polysaccharides inhibit ovarian cancer cell growth via microRNA-27a/FBXW7 signaling pathway. Bioscience reports 41 32159214
2011 The two faces of FBW7 in cancer drug resistance. BioEssays : news and reviews in molecular, cellular and developmental biology 41 22006825
2022 Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome. American journal of human genetics 37 35395208
2018 The AGO proteins: an overview. Biological chemistry 35 29447113
2012 SEL-10/Fbw7-dependent negative feedback regulation of LIN-45/Braf signaling in C. elegans via a conserved phosphodegron. Genes & development 35 23154983
2011 The F-box protein Fbw7 is required for cerebellar development. Developmental biology 34 21827743
2019 miR-25-3p promotes glioma cell proliferation and migration by targeting FBXW7 and DKK3. Experimental and therapeutic medicine 33 31258712
2015 Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway. International journal of oncology 33 25955618
2015 Regulating Fbw7 on the road to cancer. Seminars in cancer biology 32 26459133
2023 FBXW7 in breast cancer: mechanism of action and therapeutic potential. Journal of experimental & clinical cancer research : CR 31 37658431
2019 MiR-223 promotes oral squamous cell carcinoma proliferation and migration by regulating FBXW7. Cancer biomarkers : section A of Disease markers 31 30883339
2015 Fbw7 and its counteracting forces in stem cells and cancer: Oncoproteins in the balance. Seminars in cancer biology 31 26410034
2008 FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leukemia research 31 18485478
2022 FBXW7 and the Hallmarks of Cancer: Underlying Mechanisms and Prospective Strategies. Frontiers in oncology 30 35515121
2016 Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer. Oncotarget 30 27409838
2012 The C. elegans F-box proteins LIN-23 and SEL-10 antagonize centrosome duplication by regulating ZYG-1 levels. Journal of cell science 30 22623721
2009 Adenovirus E1A inhibits SCF(Fbw7) ubiquitin ligase. The Journal of biological chemistry 30 19679664
2024 FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer. Journal of experimental & clinical cancer research : CR 29 38281999
2022 KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis. Cell death & disease 28 35428764
2019 SCFFBXW7/GSK3β-Mediated GFI1 Degradation Suppresses Proliferation of Gastric Cancer Cells. Cancer research 28 31289136
2021 Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12. Nature communications 27 33824312
2017 Multivalent Interactions with Fbw7 and Pin1 Facilitate Recognition of c-Jun by the SCFFbw7 Ubiquitin Ligase. Structure (London, England : 1993) 26 29225075
2022 Insulin action and resistance are dependent on a GSK3β-FBXW7-ERRα transcriptional axis. Nature communications 25 35440636
2021 Implications of FBXW7 in Neurodevelopment and Neurodegeneration: Molecular Mechanisms and Therapeutic Potential. Frontiers in cellular neuroscience 25 34512273
2023 FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2. Cell death & disease 23 36934104
2020 FBW7 regulates HIF-1α/VEGF pathway in the IL-1β induced chondrocytes degeneration. European review for medical and pharmacological sciences 23 32572904
2019 miRNA-129/FBW7/NF-κB, a Novel Regulatory Pathway in Inflammatory Bowel Disease. Molecular therapy. Nucleic acids 23 31945730
2015 Emerging roles for the FBXW7 ubiquitin ligase in leukemia and beyond. Current opinion in cell biology 23 26426760
2023 Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers. Frontiers in oncology 22 37064111
2020 Myeloid FBW7 deficiency disrupts redox homeostasis and aggravates dietary-induced insulin resistance. Redox biology 22 32853822
2015 Regulation mechanism of Fbxw7-related signaling pathways (Review). Oncology reports 22 26324296
2022 FBXW7-mediated ERK3 degradation regulates the proliferation of lung cancer cells. Experimental & molecular medicine 21 35022544
2020 FBXW7 promotes pathological cardiac hypertrophy by targeting EZH2-SIX1 signaling. Experimental cell research 21 32380038
2022 Myeloid Fbxw7 Prevents Pulmonary Fibrosis by Suppressing TGF-β Production. Frontiers in immunology 20 35069531
2020 Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy. Cancer biology & therapy 20 33336620
2018 FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1. Cancer science 20 30302867
2021 Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair. Frontiers in cell and developmental biology 19 34760892
2017 Fbxw7 haploinsufficiency loses its protection against DNA damage and accelerates MNU-induced gastric carcinogenesis. Oncotarget 19 28422719
2019 FBXW7 Mutations Promote Cell Proliferation, Migration, and Invasion in Cervical Cancer. Genetic testing and molecular biomarkers 17 31161818

Missed literature

Know a paper Affinage missed for FBXW7? Flag it for the maintainers and the community.

No submissions yet.